Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial.

Archives of drug information

Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A.
PMID: 22022341
Arch Drug Inf. 2011 Sep;4(3):33-41. doi: 10.1111/j.1753-5174.2011.00035.x.

INTRODUCTION: Recombinant human erythropoietin (r-HuEPO) is used to treat symptomatic anaemia due to chemotherapy. A new r-HuEPO, Epoetin theta (Eporatio®), was investigated and compared to placebo in a randomised, double-blind clinical trial in adult cancer patients receiving nonplatinum-based chemotherapy....

Cite
Tjulandin SA, Bias P, Elsässer R, et al. Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial. Arch Drug Inf. 2011;4(3):33-41doi: 10.1111/j.1753-5174.2011.00035.x.
Tjulandin, S. A., Bias, P., Elsässer, R., Gertz, B., Kohler, E., & Buchner, A. (2011). Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial. Archives of drug information, 4(3), 33-41. https://doi.org/10.1111/j.1753-5174.2011.00035.x
Tjulandin, Sergei A, et al. "Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial." Archives of drug information vol. 4,3 (2011): 33-41. doi: https://doi.org/10.1111/j.1753-5174.2011.00035.x
Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A. Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial. Arch Drug Inf. 2011 Sep;4(3):33-41. doi: 10.1111/j.1753-5174.2011.00035.x. PMID: 22022341; PMCID: PMC3193379.
Copy Download .nbib Format: NLM
Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial.

Archives of drug information

Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A.
PMID: 21331363
Arch Drug Inf. 2010 Sep;3(3):45-53. doi: 10.1111/j.1753-5174.2010.00030.x.

INTRODUCTION: Recombinant human erythropoietin (r-HuEPO) is used to treat symptomatic anaemia due to chemotherapy. A new r-HuEPO, Epoetin theta (Eporatio®), was investigated and compared to placebo and Epoetin beta in a randomised, double-blind clinical trial in adult cancer patients...

Cite
Tjulandin SA, Bias P, Elsässer R, et al. Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial. Arch Drug Inf. 2010;3(3):45-53doi: 10.1111/j.1753-5174.2010.00030.x.
Tjulandin, S. A., Bias, P., Elsässer, R., Gertz, B., Kohler, E., & Buchner, A. (2010). Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial. Archives of drug information, 3(3), 45-53. https://doi.org/10.1111/j.1753-5174.2010.00030.x
Tjulandin, Sergei A, et al. "Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial." Archives of drug information vol. 3,3 (2010): 45-53. doi: https://doi.org/10.1111/j.1753-5174.2010.00030.x
Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A. Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial. Arch Drug Inf. 2010 Sep;3(3):45-53. doi: 10.1111/j.1753-5174.2010.00030.x. PMID: 21331363; PMCID: PMC3038197.
Copy Download .nbib Format: NLM
Double siRNA-targeting of cIAP2 and LIVIN results in synergetic sensitization of HCT-116 cells to oxaliplatin treatment.

OncoTargets and therapy

Bavykin AS, Korotaeva AA, Poyarkov SV, Syrtsev AV, Tjulandin SA, Karpukhin AV.
PMID: 24098083
Onco Targets Ther. 2013 Sep 23;6:1333-40. doi: 10.2147/OTT.S44893. eCollection 2013.

PURPOSE: Most colon cancers show low sensitivity to treatment with oxaliplatin and a specific strategy is needed to overcome this problem. Our approach uses RNA interference to silence the expression of target genes responsible for the development of oxaliplatin...

Cite
Bavykin AS, Korotaeva AA, Poyarkov SV, et al. Double siRNA-targeting of cIAP2 and LIVIN results in synergetic sensitization of HCT-116 cells to oxaliplatin treatment. Onco Targets Ther. 2013;6:1333-40doi: 10.2147/OTT.S44893.
Bavykin, A. S., Korotaeva, A. A., Poyarkov, S. V., Syrtsev, A. V., Tjulandin, S. A., & Karpukhin, A. V. (2013). Double siRNA-targeting of cIAP2 and LIVIN results in synergetic sensitization of HCT-116 cells to oxaliplatin treatment. OncoTargets and therapy, 61333-40. https://doi.org/10.2147/OTT.S44893
Bavykin, Andrey S, et al. "Double siRNA-targeting of cIAP2 and LIVIN results in synergetic sensitization of HCT-116 cells to oxaliplatin treatment." OncoTargets and therapy vol. 6 (2013): 1333-40. doi: https://doi.org/10.2147/OTT.S44893
Bavykin AS, Korotaeva AA, Poyarkov SV, Syrtsev AV, Tjulandin SA, Karpukhin AV. Double siRNA-targeting of cIAP2 and LIVIN results in synergetic sensitization of HCT-116 cells to oxaliplatin treatment. Onco Targets Ther. 2013 Sep 23;6:1333-40. doi: 10.2147/OTT.S44893. eCollection 2013. PMID: 24098083; PMCID: PMC3789649.
Copy Download .nbib Format: NLM
Characteristics of Patients with Pleural Mesothelioma in the Russian Federation.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Gorbounova VA, Bychkov MB, Vladimirova LY, Levchenko EV, Karpenko TD, Mamontov OY, Burmistrov V, Novick D, Rajan N, Sholokhova E, Solovyenko Y, Tjulandin SA.
PMID: 27202164
Value Health. 2014 Nov;17(7):A617. doi: 10.1016/j.jval.2014.08.2178. Epub 2014 Oct 26.

No abstract available.

Cite
Gorbounova VA, Bychkov MB, Vladimirova LY, et al. Characteristics of Patients with Pleural Mesothelioma in the Russian Federation. Value Health. 2014;17(7):A617doi: 10.1016/j.jval.2014.08.2178.
Gorbounova, V. A., Bychkov, M. B., Vladimirova, L. Y., Levchenko, E. V., Karpenko, T. D., Mamontov, O. Y., Burmistrov, V., Novick, D., Rajan, N., Sholokhova, E., Solovyenko, Y., & Tjulandin, S. A. (2014). Characteristics of Patients with Pleural Mesothelioma in the Russian Federation. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A617. https://doi.org/10.1016/j.jval.2014.08.2178
Gorbounova, V A, et al. "Characteristics of Patients with Pleural Mesothelioma in the Russian Federation." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A617. doi: https://doi.org/10.1016/j.jval.2014.08.2178
Gorbounova VA, Bychkov MB, Vladimirova LY, Levchenko EV, Karpenko TD, Mamontov OY, Burmistrov V, Novick D, Rajan N, Sholokhova E, Solovyenko Y, Tjulandin SA. Characteristics of Patients with Pleural Mesothelioma in the Russian Federation. Value Health. 2014 Nov;17(7):A617. doi: 10.1016/j.jval.2014.08.2178. Epub 2014 Oct 26. PMID: 27202164.
Copy Download .nbib Format: NLM
Nuclear Protein of the Testis Midline Carcinoma Masquerading as a Primary Mediastinal Seminoma.

Rare tumors

Sayapina MS, Savelov NA, Karseladze AI, Bulanov AA, Tryakin AA, Nosov DA, Garin AM, Tjulandin SA.
PMID: 27441078
Rare Tumors. 2016 Jun 28;8(2):6241. doi: 10.4081/rt.2016.6241. eCollection 2016 Jun 28.

Nuclear protein of the testis (NUT) midline carcinomas are rare aggressive carcinomas characterized by chromosomal rearrangements that involve the gene encoding the NUT. This article reviews the clinicopathologic features and the differential diagnosis of these malignancies.

Cite
Sayapina MS, Savelov NA, Karseladze AI, et al. Nuclear Protein of the Testis Midline Carcinoma Masquerading as a Primary Mediastinal Seminoma. Rare Tumors. 2016;8(2):6241doi: 10.4081/rt.2016.6241.
Sayapina, M. S., Savelov, N. A., Karseladze, A. I., Bulanov, A. A., Tryakin, A. A., Nosov, D. A., Garin, A. M., & Tjulandin, S. A. (2016). Nuclear Protein of the Testis Midline Carcinoma Masquerading as a Primary Mediastinal Seminoma. Rare tumors, 8(2), 6241. https://doi.org/10.4081/rt.2016.6241
Sayapina, Maria S, et al. "Nuclear Protein of the Testis Midline Carcinoma Masquerading as a Primary Mediastinal Seminoma." Rare tumors vol. 8,2 (2016): 6241. doi: https://doi.org/10.4081/rt.2016.6241
Sayapina MS, Savelov NA, Karseladze AI, Bulanov AA, Tryakin AA, Nosov DA, Garin AM, Tjulandin SA. Nuclear Protein of the Testis Midline Carcinoma Masquerading as a Primary Mediastinal Seminoma. Rare Tumors. 2016 Jun 28;8(2):6241. doi: 10.4081/rt.2016.6241. eCollection 2016 Jun 28. PMID: 27441078; PMCID: PMC4935827.
Copy Download .nbib Format: NLM
[Experience in training of paramedical personnel].

Fel'dsher i akusherka

Tiuliandin AD.
PMID: 4484392
Feldsher Akush. 1972 Jun;37(6):41-3.

No abstract available.

Cite
Tiuliandin AD. Opyt povysheniia kvalifikatsii srednikh meditsinskikh rabotnikov. [Experience in training of paramedical personnel]. Feldsher Akush. 1972;37(6):41-3
Tiuliandin, A. D. (1972). Opyt povysheniia kvalifikatsii srednikh meditsinskikh rabotnikov. [Experience in training of paramedical personnel]. Fel'dsher i akusherka, 37(6), 41-3.
Tiuliandin, A D. "Opyt povysheniia kvalifikatsii srednikh meditsinskikh rabotnikov." [Experience in training of paramedical personnel]. Fel'dsher i akusherka vol. 37,6 (1972): 41-3.
Tiuliandin AD. Opyt povysheniia kvalifikatsii srednikh meditsinskikh rabotnikov. [Experience in training of paramedical personnel]. Feldsher Akush. 1972 Jun;37(6):41-3. Russian. PMID: 4484392.
Copy Download .nbib Format: NLM
Real-world treatment patterns among patients with advanced gastric cancer in Russia: a chart review study.

Journal of drug assessment

Tjulandin SA, Tryakin AA, Besova NS, Sholokhova E, Ivanova JI, Cheng WY, Schmerold LM, Thompson-Leduc P, Novick D.
PMID: 31656688
J Drug Assess. 2019 Sep 17;8(1):150-158. doi: 10.1080/21556660.2019.1669610. eCollection 2019.

No abstract available.

Cite
Tjulandin SA, Tryakin AA, Besova NS, et al. Real-world treatment patterns among patients with advanced gastric cancer in Russia: a chart review study. J Drug Assess. 2019;8(1):150-158doi: 10.1080/21556660.2019.1669610.
Tjulandin, S. A., Tryakin, A. A., Besova, N. S., Sholokhova, E., Ivanova, J. I., Cheng, W. Y., Schmerold, L. M., Thompson-Leduc, P., & Novick, D. (2019). Real-world treatment patterns among patients with advanced gastric cancer in Russia: a chart review study. Journal of drug assessment, 8(1), 150-158. https://doi.org/10.1080/21556660.2019.1669610
Tjulandin, Sergei A, et al. "Real-world treatment patterns among patients with advanced gastric cancer in Russia: a chart review study." Journal of drug assessment vol. 8,1 (2019): 150-158. doi: https://doi.org/10.1080/21556660.2019.1669610
Tjulandin SA, Tryakin AA, Besova NS, Sholokhova E, Ivanova JI, Cheng WY, Schmerold LM, Thompson-Leduc P, Novick D. Real-world treatment patterns among patients with advanced gastric cancer in Russia: a chart review study. J Drug Assess. 2019 Sep 17;8(1):150-158. doi: 10.1080/21556660.2019.1669610. eCollection 2019. PMID: 31656688; PMCID: PMC6792042.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries